The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

Johnson & Johnson's Akeega is opening new fronts in prostate cancer treatment with a fresh FDA approval making it the first ...

Horsham: Johnson & Johnson has announced the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug ...

Erectile, Ejaculatory Dysfunction More Common in Cardiac Patients In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it. Prostate ...

The FDA approved niraparib and abiraterone acetate plus prednisone for BRCA2-mutated mCSPC, based on the AMPLITUDE trial's rPFS results. FDA approves a new treatment combining niraparib and ...

Image: prostate cancer cells. Credit: Mateus Crespo, Ana Ferreira, Daniel Nava Rodrigues and Johann de Bono Men with faults in the BRCA2 gene have an increased risk of prostate cancer and could ...

Using advanced computational genomics, Johns Hopkins investigators discovered how prostate cancer develops resistance to ...

Prostate cancer guidelines should change so that all men from the age of 40 with mutations in either the BRCA1 or BRCA2 gene are offered regular PSA testing to detect early signs of the disease, ...

" [They] reinforce the role of BRCA2 and ATM as key determinants of aggressive prostate cancer phenotypes. The limited ...

Ribbon structure of the BRCA2 protein. Mutations in the BRCA2 gene are linked to increased risk of breast cancer. New work from UC Davis shows how individual BRCA2 proteins work to repair damaged DNA, ...

The FDA has approved Akeega plus prednisone for adults with deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer.